+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032- Product Image
Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032- Product Image
Sale

Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4986033
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Viral Vector & Plasmid DNA Manufacturing Market is projected to reach USD 6.10 Billion in 2026. It is expected to continue growing at a CAGR of 16.91%, reaching USD 15.67 Billion by 2032.

Viral vector and plasmid DNA manufacturing has become a critical capacity bottleneck and value driver for cell therapy, gene therapy, mRNA, vaccine, and genome-editing pipelines. Demand is anchored by approved adeno-associated virus (AAV), lentiviral, adenoviral, and plasmid-enabled products, as well as a broad clinical pipeline that requires scalable, GMP-compliant production, validated analytics, and reliable supply of high-quality starting materials.

For contract development and manufacturing organizations (CDMOs) and therapy developers, the industry is defined by three imperatives: shortening development timelines, increasing batch consistency, and expanding flexible capacity. Sponsors increasingly evaluate partners on end-to-end capabilities spanning cell line development, upstream and downstream process development, analytical testing, release documentation, fill-finish integration, cold-chain readiness, and regulatory inspection preparedness.

Transformative Shifts in the Manufacturing Landscape

The landscape is shifting from artisanal, campaign-based production toward industrialized platforms built around closed processing, single-use bioreactors, high-throughput analytics, automation, and standardized quality systems. AAV and lentiviral vectors remain central to in vivo gene therapy and ex vivo cell therapy, while plasmid DNA is gaining strategic importance as a starting material for viral vectors, mRNA templates, genome-editing tools, and DNA vaccine applications.

Capacity strategy is also changing. Large biopharma organizations are balancing internal manufacturing investments with CDMO partnerships to reduce supply risk, while emerging biotechnology firms rely on external partners for speed, technical depth, and regulatory know-how. The most competitive manufacturers are moving from capacity selling to platform selling, offering validated workflows that reduce comparability risk, strengthen process transfer outcomes, and support lifecycle management from early clinical supply to commercial manufacturing.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly used to improve process development, deviation management, and quality control across viral vector and plasmid DNA manufacturing. Practical applications include predictive bioreactor monitoring, design-of-experiments acceleration, chromatography optimization, anomaly detection, automated batch record review, raw material variability assessment, and advanced analysis of potency, purity, and safety datasets.

The cumulative impact is not a replacement for GMP expertise but a measurable improvement in decision speed, process understanding, and manufacturing robustness. AI-enabled digital twins and advanced analytics help teams anticipate yield variability, identify critical process parameters, and reduce failed runs. Industry leaders are prioritizing validated, explainable AI systems that can withstand regulatory scrutiny and support data integrity expectations under FDA, EMA, ICH, and PIC/S quality frameworks.

Key Regional Insights

North America leads global commercialization momentum due to the concentration of FDA-regulated gene therapy approvals, venture-backed biotechnology companies, academic translational centers, specialized CDMO infrastructure, and a mature ecosystem for GMP viral vector and plasmid DNA manufacturing. The United States remains the anchor market, supported by advanced therapy approvals and deep clinical trial activity, while Canada contributes clinical research capacity, public biomanufacturing investment, and a growing talent base for biologics and cell and gene therapy production.

Europe is characterized by strong regulatory maturity, advanced cell and gene therapy clusters, and public-private manufacturing initiatives across the European Union and the United Kingdom. The region benefits from established advanced therapy medicinal product frameworks, hospital-linked treatment networks, and cross-border scientific collaboration. Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, Singapore, and Australia invest in clinical development, bioprocessing talent, domestic manufacturing resilience, plasmid DNA supply, and technology transfer capabilities.

Latin America is earlier in adoption but shows rising interest in advanced therapies through Brazil and Mexico, where public health systems, pharmaceutical manufacturing bases, and clinical research infrastructure are shaping long-term opportunity. The Middle East is building life sciences hubs through healthcare diversification strategies, particularly in GCC countries that are prioritizing specialty care, biologics infrastructure, and strategic manufacturing partnerships. Africa remains nascent, with opportunities tied to vaccine manufacturing, technology transfer, workforce training, regulatory strengthening, and regional biomanufacturing capacity building.

Key Group Insights

The G7 remains the most influential demand, regulatory, and innovation bloc because it includes major health authorities, advanced therapy developers, payer systems, academic research centers, and mature GMP infrastructure. NATO markets overlap with many high-income biopharma economies, supporting policy discussions around supply chain security, critical medicines, biologics manufacturing, and resilience for advanced therapy inputs such as viral vectors, plasmid DNA, single-use systems, and specialty reagents.

The European Union plays a central role through harmonized regulatory pathways, cross-border clinical trial coordination, and funding mechanisms that support advanced therapy medicinal products and biomanufacturing modernization. BRICS countries are increasingly relevant as China, India, and Brazil expand biologics capacity, clinical research activity, vaccine platforms, and local manufacturing ambitions, while Russia’s participation is affected by geopolitical constraints and supply chain limitations.

ASEAN is emerging as a regional manufacturing and clinical operations corridor, with Singapore acting as a high-value bioprocessing hub and neighboring countries strengthening healthcare access, clinical infrastructure, and investment promotion for life sciences. The GCC is positioning life sciences as part of economic diversification, with opportunities in fill-finish, technology transfer, specialty hospital networks, regulatory capability building, and partnerships that can support future viral vector and plasmid DNA manufacturing readiness.

Key Country Insights

The United States is the leading commercial and regulatory reference point for viral vector and plasmid DNA manufacturing, supported by FDA approvals, venture capital, clinical trial depth, academic innovation, and specialized CDMO capacity. Canada adds clinical research strength and public biomanufacturing investments, while Mexico offers proximity advantages for broader life sciences supply chains and medical manufacturing. Brazil is the leading Latin American opportunity due to its pharmaceutical base, public health infrastructure, vaccine experience, and growing interest in advanced therapy access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support advanced therapy research, GMP manufacturing, translational medicine, and hospital-based treatment networks. The United Kingdom benefits from strong cell and gene therapy clinical infrastructure, Germany from engineering depth and bioprocessing expertise, France from national biomanufacturing initiatives, Italy from academic and hospital-linked advanced therapy activity, and Spain from clinical trial participation and biomedical research networks. Russia has scientific capabilities but faces geopolitical, regulatory, financing, and supply chain constraints that limit integration with global advanced therapy manufacturing networks.

China is scaling aggressively across gene therapy, plasmid DNA, viral vector development, and CDMO services, supported by expanding clinical activity and domestic innovation policies. India is strengthening biologics, vaccines, plasmid production, and cost-efficient process development capabilities, while Japan maintains a favorable regenerative medicine framework and strong regulatory experience with advanced therapies. South Korea is investing in biomanufacturing scale, quality systems, and technology-driven life sciences infrastructure, and Australia remains important for early-phase clinical trials, translational research, and Asia-Pacific advanced therapy collaboration.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize modular capacity, platform processes, and integrated analytical capabilities to reduce lead times and improve right-first-time manufacturing. Investments in high-yield producer systems, closed processing, scalable purification, robust plasmid DNA production, contamination control, and rapid release testing are essential for competitive differentiation in viral vector and plasmid DNA manufacturing.

CDMOs and therapy developers should build supplier redundancy for critical raw materials, strengthen plasmid DNA sourcing strategies, and maintain transparent technology transfer playbooks. Executive teams should also invest in regulatory intelligence, workforce development, digital batch records, data integrity controls, and validated AI analytics to improve compliance, reduce deviations, support comparability packages, and increase sponsor confidence across clinical and commercial programs.

Research Methodology

This executive summary is based on secondary research and industry triangulation using publicly available regulatory, scientific, and technical sources. Inputs include FDA and EMA advanced therapy guidance, public approval records, clinical trial registries, health authority publications, peer-reviewed manufacturing literature, pharmacopeial references, and recognized bioprocessing industry commentary.

The assessment emphasizes verified trends rather than speculative forecasts. Regional, group, and country insights were evaluated through observable indicators such as regulatory maturity, clinical development activity, CDMO presence, biomanufacturing investment, public policy initiatives, workforce availability, quality system readiness, and supply chain preparedness for viral vectors and plasmid DNA.

Conclusion

Viral vector and plasmid DNA manufacturing is entering an execution-focused phase in which quality, speed, scalability, data integrity, and regulatory reliability determine competitive positioning. Demand is expanding across gene therapy, cell therapy, mRNA, genome editing, and next-generation vaccine platforms, but capacity alone is no longer sufficient to meet sponsor expectations or regulatory requirements.

The strongest manufacturers will combine flexible infrastructure, proven platform technologies, advanced analytics, resilient raw material strategies, and global regulatory competence. Organizations that industrialize processes while preserving scientific adaptability will be best positioned to support the evolving advanced therapy manufacturing ecosystem.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Viral Vector & Plasmid DNA Manufacturing Market, by Product Type
7.1. Introduction
7.2. Plasmid DNA
7.3. Viral Vector
7.3.1. Adeno-Associated Viral Vectors
7.3.2. Adenoviral Vectors
7.3.3. Herpes Simplex Virus (HSV) Vectors
7.3.4. Lentiviral Vectors
7.3.5. Retroviral Vectors
8. Viral Vector & Plasmid DNA Manufacturing Market, by Service Type
8.1. Introduction
8.2. Analytical Testing
8.3. Manufacturing
8.4. Process Development
8.4.1. Downstream Optimization
8.4.2. Formulation Development
8.4.3. Scale-Up/Technology Transfer
8.4.4. Upstream Optimization
8.5. Regulatory & CMC Support
9. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow Stage
9.1. Introduction
9.2. Downstream Processing
9.2.1. Capture
9.2.2. Clarification
9.2.3. Concentration/Buffer Exchange
9.2.4. Intermediate Purification
9.2.5. Polishing
9.3. Fill & Finish
9.4. Release & Stability Testing
9.5. Upstream Processing
9.5.1. Bioreactor Production
9.5.2. Cell Expansion
9.5.3. Transfection/Transduction
10. Viral Vector & Plasmid DNA Manufacturing Market, by Production Platform
10.1. Introduction
10.2. Bacterial
10.3. Cell-Free Systems
10.4. Insect
10.5. Mammalian
10.6. Yeast
11. Viral Vector & Plasmid DNA Manufacturing Market, by Bioprocess Mode
11.1. Introduction
11.2. Batch
11.3. Culture Format
11.3.1. Adherent
11.3.2. Suspension
11.4. Fed-Batch
11.5. Perfusion
12. Viral Vector & Plasmid DNA Manufacturing Market, by Source
12.1. Introduction
12.2. In-House Manufacturing
12.3. Outsourced/CDMO
13. Viral Vector & Plasmid DNA Manufacturing Market, by Application
13.1. Introduction
13.2. Cell Therapy
13.3. Gene Editing
13.4. Gene Therapy
13.5. Oncolytic Virotherapy
13.6. Research & Developement
13.7. Vaccine Development
14. Viral Vector & Plasmid DNA Manufacturing Market, by End User
14.1. Introduction
14.2. Biopharmaceutical Companies
14.3. Contract Development & Manufacturing Organizations (CDMOs)
14.4. Contract Research Organizations (CROs)
14.5. Research Institutions
15. Viral Vector & Plasmid DNA Manufacturing Market, by Disease Area
15.1. Introduction
15.2. Cardiovascular
15.3. Hepatic Diseases
15.4. Infectious Diseases
15.5. Metabolic/Endocrine
15.6. Musculoskeletal
15.7. Neurology
15.8. Oncology
15.9. Ophthalmology
15.10. Rare Genetic Disorders
16. Viral Vector & Plasmid DNA Manufacturing Market, by Region
16.1. Asia-Pacific
16.2. North America
16.3. Latin America
16.4. Europe
16.5. Middle East
16.6. Africa
17. Viral Vector & Plasmid DNA Manufacturing Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Viral Vector & Plasmid DNA Manufacturing Market, by Country
18.1. United States
18.2. Germany
18.3. China
18.4. United Kingdom
18.5. India
18.6. Japan
18.7. Russia
18.8. Brazil
18.9. Canada
18.10. Italy
18.11. Mexico
18.12. France
18.13. Spain
18.14. Australia
18.15. South Korea
19. Competitive Landscape
19.1. Market Share Analysis, 2025
19.2. FPNV Positioning Matrix, 2025
19.3. Market Concentration Analysis, 2025
19.3.1. Concentration Ratio (CR)
19.3.2. Herfindahl Hirschman Index (HHI)
19.4. Recent Developments & Impact Analysis, 2025
19.5. Product Portfolio Analysis, 2025
19.6. Benchmarking Analysis, 2025
20. Company Profiles
20.1. Advanced BioScience Laboratories, Inc.
20.2. Akron Biotech
20.3. Aldevron, LLC
20.4. Avid Bioservices, Inc.
20.5. Batavia Biosciences B.V.
20.6. BioNTech IMFS GmbH
20.7. BioSpace, Inc.
20.8. Biovian Oy
20.9. c-LEcta GmbH
20.10. Catalent, Inc.
20.11. Charles River Laboratories International, Inc.
20.12. Creative Biogene
20.13. Cytiva by Danaher Corporation
20.14. FILTROX AG
20.15. Forge Biologics By Ajinomoto Co., Inc.
20.16. FUJIFILM Diosynth Biotechnologies Inc.
20.17. GE HealthCare Technologies, Inc.
20.18. Genentech, Inc.
20.19. GeneOne Life Science, Inc.
20.20. Genezen Laboratories, Inc.
20.21. GenScript Biotech Corporation
20.22. Hillgene Biopharma Co., Ltd.
20.23. Kaneka Eurogentec S.A.
20.24. Lonza Group Ltd.
20.25. Merck KGaA
20.26. Miltenyi Biotec B.V. & Co. KG
20.27. Oxford Biomedica plc
20.28. POLYPLUS TRANSFECTION S.A.
20.29. REGENXBIO Inc.
20.30. Revvity, Inc.
20.31. Takara Bio Inc.
20.32. Thermo Fisher Scientific Inc.
20.33. Twist Bioscience Corporation
20.34. uniQure N.V.
20.35. Wuxi AppTec Co., Ltd.
List of Figures
FIGURE 1. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025 VS 2032 (%)
FIGURE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025 VS 2032 (%)
FIGURE 23. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 27. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 29. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 31. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PLASMID DNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PLASMID DNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PLASMID DNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ADENO-ASSOCIATED VIRAL VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ADENO-ASSOCIATED VIRAL VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ADENO-ASSOCIATED VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ADENOVIRAL VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ADENOVIRAL VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ADENOVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL LENTIVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL RETROVIRAL VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL RETROVIRAL VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL RETROVIRAL VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANALYTICAL TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANALYTICAL TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ANALYTICAL TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL DOWNSTREAM OPTIMIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL DOWNSTREAM OPTIMIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL DOWNSTREAM OPTIMIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SCALE-UP/TECHNOLOGY TRANSFER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SCALE-UP/TECHNOLOGY TRANSFER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SCALE-UP/TECHNOLOGY TRANSFER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL UPSTREAM OPTIMIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL UPSTREAM OPTIMIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL UPSTREAM OPTIMIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL REGULATORY & CMC SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL REGULATORY & CMC SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL REGULATORY & CMC SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL DOWNSTREAM PROCESSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CAPTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CAPTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CAPTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CLARIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CLARIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL CLARIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CONCENTRATION/BUFFER EXCHANGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CONCENTRATION/BUFFER EXCHANGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CONCENTRATION/BUFFER EXCHANGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL INTERMEDIATE PURIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL INTERMEDIATE PURIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL INTERMEDIATE PURIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL POLISHING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL POLISHING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL POLISHING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL FILL & FINISH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL FILL & FINISH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL FILL & FINISH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RELEASE & STABILITY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL RELEASE & STABILITY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL RELEASE & STABILITY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL UPSTREAM PROCESSING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL BIOREACTOR PRODUCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL BIOREACTOR PRODUCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL BIOREACTOR PRODUCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CELL EXPANSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CELL EXPANSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL CELL EXPANSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL TRANSFECTION/TRANSDUCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL TRANSFECTION/TRANSDUCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL TRANSFECTION/TRANSDUCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CELL-FREE SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL CELL-FREE SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CELL-FREE SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL INSECT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL INSECT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL INSECT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL MAMMALIAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL MAMMALIAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL MAMMALIAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL YEAST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL YEAST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL YEAST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL BATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL BATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL BATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CULTURE FORMAT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL CULTURE FORMAT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL CULTURE FORMAT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ADHERENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ADHERENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ADHERENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL FED-BATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL FED-BATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL FED-BATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL PERFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL PERFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL PERFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL IN-HOUSE MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL OUTSOURCED/CDMO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL OUTSOURCED/CDMO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL OUTSOURCED/CDMO MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL ONCOLYTIC VIROTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL ONCOLYTIC VIROTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL ONCOLYTIC VIROTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL RESEARCH & DEVELOPEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL RESEARCH & DEVELOPEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL RESEARCH & DEVELOPEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL VACCINE DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL VACCINE DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL VACCINE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL HEPATIC DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL HEPATIC DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL HEPATIC DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL METABOLIC/ENDOCRINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL METABOLIC/ENDOCRINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL METABOLIC/ENDOCRINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL MUSCULOSKELETAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL MUSCULOSKELETAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL MUSCULOSKELETAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 184. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 186. GLOBAL RARE GENETIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 187. GLOBAL RARE GENETIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL RARE GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 189. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2017-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 205. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 206. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 207. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 208. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 209. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 210. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 211. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 212. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 213. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 214. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 215. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2017-2032 (USD MILLION)
TABLE 216. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 217. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 218. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. NORTH AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 220. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 221. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 222. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 223. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 224. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 225. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 226. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 227. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 228. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 229. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 230. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2017-2032 (USD MILLION)
TABLE 231. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 232. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 233. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. LATIN AMERICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 235. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 236. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 237. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 238. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 239. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 240. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 241. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 242. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 243. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 244. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 245. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2017-2032 (USD MILLION)
TABLE 246. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 247. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 248. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. EUROPE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 254. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 255. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 256. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 257. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 258. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 259. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 260. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2017-2032 (USD MILLION)
TABLE 261. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 262. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. MIDDLE EAST VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 265. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 266. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 267. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 268. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 269. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 270. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 271. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 272. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 273. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 274. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 275. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2017-2032 (USD MILLION)
TABLE 276. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 277. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 278. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 280. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 281. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 282. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 283. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 284. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 285. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 286. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 287. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 288. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 289. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 290. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 291. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2017-2032 (USD MILLION)
TABLE 292. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 293. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 294. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. ASEAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 296. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 297. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 298. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 299. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 300. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 301. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 302. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 303. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 304. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 305. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 306. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2017-2032 (USD MILLION)
TABLE 307. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 308. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 309. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 310. GCC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW STAGE, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2017-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCTION PLATFORM, 2017-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY BIOPROCESS MODE, 2017-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CULTURE FORMAT, 2017-2032 (USD MILLION)
TABLE 322. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 323. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 324. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 325. EUROPEAN UNION VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 326. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 327. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 328. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 329. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 330. BRICS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 331. BRICS VIRAL

Companies Mentioned

  • Advanced BioScience Laboratories, Inc.
  • Akron Biotech
  • Aldevron, LLC
  • Avid Bioservices, Inc.
  • Batavia Biosciences B.V.
  • BioNTech IMFS GmbH
  • BioSpace, Inc.
  • Biovian Oy
  • c-LEcta GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • Cytiva by Danaher Corporation
  • FILTROX AG
  • Forge Biologics By Ajinomoto Co., Inc.
  • FUJIFILM Diosynth Biotechnologies Inc.
  • GE HealthCare Technologies, Inc.
  • Genentech, Inc.
  • GeneOne Life Science, Inc.
  • Genezen Laboratories, Inc.
  • GenScript Biotech Corporation
  • Hillgene Biopharma Co., Ltd.
  • Kaneka Eurogentec S.A.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec B.V. & Co. KG
  • Oxford Biomedica plc
  • POLYPLUS TRANSFECTION S.A.
  • REGENXBIO Inc.
  • Revvity, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
  • uniQure N.V.
  • Wuxi AppTec Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.1 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.67 Billion
Compound Annual Growth Rate16.9%
Regions CoveredGlobal
No. of Companies Mentioned36

Related Topics

Related Reports

Viral Vectors and Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report by Vector Type, Workflow, Application, End-use, Disease, Region, and Segment Forecasts, 2026-2033 - Product Image

Viral Vectors and Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report by Vector Type, Workflow, Application, End-use, Disease, Region, and Segment Forecasts, 2026-2033

  • Report
  • 120 Pages
  • Global
From
Plasmid DNA CDMO Service Market - Global Forecast 2026-2032 - Product Image

Plasmid DNA CDMO Service Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Viral Vector and Plasmid DNA Manufacturing Market Outlook 2026-2034: Market Share, and Growth Analysis by Product Type (Plasmid DNA, Viral Vector, Non-Viral Vector), Application - Product Image

Viral Vector and Plasmid DNA Manufacturing Market Outlook 2026-2034: Market Share, and Growth Analysis by Product Type (Plasmid DNA, Viral Vector, Non-Viral Vector), Application

  • Report
  • 160 Pages
  • Global
From
Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 189 Pages
  • Global
From
Viral Vectors and Plasmid DNA Market Report 2026 - Product Image

Viral Vectors and Plasmid DNA Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.